BOEM S8219 Public Comment Solicitation - Offshore Energy and Mineral Management

The Bureau of Ocean Energy Management (BOEM) has published document S8219 for public review and comment via Regulations.gov under docket BOEM-2026-0298. The document pertains to BOEM's regulatory activities involving offshore energy development, marine mineral resources, or environmental review processes on the Outer Continental Shelf. Interested parties have until April 17, 2026 to submit comments on the proposed matter.

Huntington Disease Ultrasound Trial, Fujian Medical University

Fujian Medical University registered a Phase 1/2 clinical trial (NCT07513844) on ClinicalTrials.gov investigating low-intensity ultrasound as a treatment for Huntington disease. The trial will assess safety and preliminary efficacy parameters in patients with the neurodegenerative condition. ClinicalTrials.gov serves as the primary public registry for clinical research conducted under FDA oversight.

Iparomlimab tovorilimab bevacizumab mesothelioma trial

NIH registered a new Phase 2 clinical trial (NCT07514793) on ClinicalTrials.gov evaluating the combination of iparomlimab, tovorilimab, and bevacizumab for the treatment of mesothelioma. The trial is sponsored by Memorial Sloan Kettering Cancer Center and appears to be an open-label study investigating this immunotherapy combination. ClinicalTrials.gov serves as the primary registry for clinical trials conducted under FDA oversight.

KHN922 injection phase 1/2 solid tumor trial

ClinicalTrials.gov posted a new clinical trial registration for KHN922 injection, a Phase 1/2 study evaluating the treatment in patients with solid tumors. The trial is registered as NCT07514975 and includes study design details such as eligibility criteria and outcome measures. This registration fulfills requirements for publicly listing clinical trials conducted under FDA oversight.

Zhejiang University FAP CAR-DC trial, end-stage dilated cardiomyopathy

The National Library of Medicine registered a new Phase 1 clinical trial (NCT07516288) on ClinicalTrials.gov, sponsored by Zhejiang University in China. The trial evaluates FAP CAR-DC cell therapy for patients with end-stage dilated cardiomyopathy. The study appears in the ClinicalTrials.gov public registry as an informational record for transparency and public awareness.

Eisai E6742 trial for systemic lupus erythematosus

ClinicalTrials.gov has registered a new clinical trial (NCT07515014) for Eisai E6742, an investigational drug for systemic lupus erythematosus. The registry entry provides study metadata including phase, eligibility criteria, enrollment information, and participating locations. Pharmaceutical companies conducting clinical trials use this public registry to satisfy transparency requirements and make trial information accessible to the public.

Oral gallium maltolate trial for recurrent glioblastoma

The National Institutes of Health registered ClinicalTrials.gov study NCT07515924, a Phase 1 interventional trial evaluating oral gallium maltolate in patients with recurrent glioblastoma. The trial will assess safety, tolerability, and maximum tolerated dose in an estimated patient cohort. Gallium maltolate is an investigational gallium-based compound under study for potential anticancer activity against glioblastoma.

BAT5906 Biosimilar vs Lucentis for Diabetic Macular Edema

Bio-Thera Solutions registered a Phase 3 clinical trial (NCT07515079) on ClinicalTrials.gov evaluating BAT5906, a biosimilar candidate referencing Lucentis (ranibizumab), for treating diabetic macular edema. The randomized, double-blind study will compare the efficacy and safety of BAT5906 injection versus reference Lucentis in patients with diabetic macular edema. Trial enrollment is ongoing.

NX-5948 versus pirtobrutinib relapsed refractory CLL SLL trial

ClinicalTrials.gov registered a new Phase 3 randomized trial (NCT07516093) comparing NX-5948 to pirtobrutinib in adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The single-arm study will evaluate efficacy and safety endpoints.

AstraZeneca studies nurandociguat drug interactions with rosuvastatin, dabigatran

AstraZeneca registered a Phase I clinical trial on ClinicalTrials.gov investigating potential drug interactions between nurandociguat and two established medications—rosuvastatin (a statin) and dabigatran (an anticoagulant). The single-arm study will evaluate pharmacokinetic parameters in healthy participants to assess how co-administration affects drug exposure and safety profiles.